|
1
|
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.
|
Arthritis Care Res (Hoboken)
|
2012
|
12.07
|
|
2
|
Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study.
|
Arthritis Rheum
|
2004
|
4.77
|
|
3
|
American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis.
|
Arthritis Care Res (Hoboken)
|
2010
|
4.65
|
|
4
|
2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features.
|
Arthritis Care Res (Hoboken)
|
2011
|
3.66
|
|
5
|
Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases.
|
JAMA
|
2011
|
3.58
|
|
6
|
Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice.
|
Arthritis Care Res (Hoboken)
|
2012
|
3.47
|
|
7
|
Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists.
|
Arthritis Rheum
|
2007
|
3.38
|
|
8
|
Gout medication treatment patterns and adherence to standards of care from a managed care perspective.
|
Mayo Clin Proc
|
2006
|
2.96
|
|
9
|
The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine.
|
J Bone Miner Res
|
2014
|
2.52
|
|
10
|
Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases.
|
JAMA
|
2012
|
2.51
|
|
11
|
Coffee, tea, and caffeine consumption and risk of rheumatoid arthritis: results from the Iowa Women's Health Study.
|
Arthritis Rheum
|
2002
|
2.43
|
|
12
|
Impact of osteoporosis treatment adherence on fracture rates in North America and Europe.
|
Am J Med
|
2009
|
2.27
|
|
13
|
Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients.
|
J Clin Epidemiol
|
2008
|
2.25
|
|
14
|
Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis.
|
J Bone Miner Res
|
2009
|
2.24
|
|
15
|
Rates of malignancy associated with juvenile idiopathic arthritis and its treatment.
|
Arthritis Rheum
|
2012
|
2.15
|
|
16
|
Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study.
|
Am J Ophthalmol
|
2012
|
2.14
|
|
17
|
Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy.
|
Arthritis Care Res (Hoboken)
|
2015
|
2.03
|
|
18
|
Re-using Mini-Sentinel data following rapid assessments of potential safety signals via modular analytic programs.
|
Pharmacoepidemiol Drug Saf
|
2013
|
2.01
|
|
19
|
Cigarette smoking and the risk of rheumatoid arthritis among postmenopausal women: results from the Iowa Women's Health Study.
|
Am J Med
|
2002
|
2.01
|
|
20
|
Obesity is not protective against fracture in postmenopausal women: GLOW.
|
Am J Med
|
2011
|
1.95
|
|
21
|
Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US medicare program.
|
Arthritis Care Res (Hoboken)
|
2013
|
1.92
|
|
22
|
Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years.
|
J Clin Endocrinol Metab
|
2006
|
1.88
|
|
23
|
Population-based assessment of adverse events associated with long-term glucocorticoid use.
|
Arthritis Rheum
|
2006
|
1.85
|
|
24
|
Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW).
|
Bone
|
2012
|
1.79
|
|
25
|
Quality of care indicators for gout management.
|
Arthritis Rheum
|
2004
|
1.77
|
|
26
|
Measuring quality in arthritis care: methods for developing the Arthritis Foundation's quality indicator set.
|
Arthritis Rheum
|
2004
|
1.76
|
|
27
|
Randomized trial to improve fracture prevention in nursing home residents.
|
Am J Med
|
2007
|
1.75
|
|
28
|
Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users.
|
Pharmacoepidemiol Drug Saf
|
2006
|
1.65
|
|
29
|
Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women.
|
Mayo Clin Proc
|
2010
|
1.62
|
|
30
|
Validity of gout diagnoses in administrative data.
|
Arthritis Rheum
|
2007
|
1.62
|
|
31
|
Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW).
|
J Bone Miner Res
|
2014
|
1.62
|
|
32
|
Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients.
|
Arthritis Rheum
|
2005
|
1.58
|
|
33
|
The epidemiology of glucocorticoid-associated adverse events.
|
Curr Opin Rheumatol
|
2008
|
1.58
|
|
34
|
Longitudinal trends in use of bone mass measurement among older americans, 1999-2005.
|
J Bone Miner Res
|
2008
|
1.55
|
|
35
|
Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
|
Arthritis Care Res (Hoboken)
|
2012
|
1.53
|
|
36
|
Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis.
|
Arthritis Res Ther
|
2011
|
1.53
|
|
37
|
OMERACT 6 brings new perspectives to rheumatology measurement research.
|
J Rheumatol
|
2003
|
1.47
|
|
38
|
Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users.
|
J Bone Miner Res
|
2008
|
1.47
|
|
39
|
Blood transfusion, alcohol use, and anthropometric risk factors for rheumatoid arthritis in older women.
|
J Rheumatol
|
2002
|
1.46
|
|
40
|
Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster.
|
JAMA
|
2013
|
1.45
|
|
41
|
Identification and validation of vertebral compression fractures using administrative claims data.
|
Med Care
|
2009
|
1.45
|
|
42
|
Recent trends in hip fracture rates by race/ethnicity among older US adults.
|
J Bone Miner Res
|
2012
|
1.44
|
|
43
|
Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment.
|
Arthritis Rheum
|
2012
|
1.43
|
|
44
|
The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents.
|
Ann Rheum Dis
|
2011
|
1.42
|
|
45
|
Empirically based composite fracture prediction model from the Global Longitudinal Study of Osteoporosis in Postmenopausal Women (GLOW).
|
J Clin Endocrinol Metab
|
2014
|
1.41
|
|
46
|
Challenges in improving the quality of osteoporosis care for long-term glucocorticoid users: a prospective randomized trial.
|
Arch Intern Med
|
2007
|
1.41
|
|
47
|
Population-based fracture risk assessment and osteoporosis treatment disparities by race and gender.
|
J Gen Intern Med
|
2009
|
1.40
|
|
48
|
Antioxidant micronutrients and risk of rheumatoid arthritis in a cohort of older women.
|
Am J Epidemiol
|
2003
|
1.35
|
|
49
|
Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis.
|
Med Care
|
2009
|
1.31
|
|
50
|
Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2).
|
Ann Rheum Dis
|
2012
|
1.31
|
|
51
|
Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems.
|
Pharmacoepidemiol Drug Saf
|
2011
|
1.30
|
|
52
|
Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women.
|
J Bone Miner Res
|
2012
|
1.29
|
|
53
|
Central DXA utilization shifts from office-based to hospital-based settings among medicare beneficiaries in the wake of reimbursement changes.
|
J Bone Miner Res
|
2012
|
1.27
|
|
54
|
Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists.
|
Arthritis Rheum
|
2007
|
1.26
|
|
55
|
Predicting fractures in an international cohort using risk factor algorithms without BMD.
|
J Bone Miner Res
|
2011
|
1.22
|
|
56
|
Treatment of rheumatoid arthritis.
|
Am J Health Syst Pharm
|
2006
|
1.21
|
|
57
|
Health services utilization after fractures: evidence from Medicare.
|
J Gerontol A Biol Sci Med Sci
|
2010
|
1.19
|
|
58
|
Relationship of weight, height, and body mass index with fracture risk at different sites in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW).
|
J Bone Miner Res
|
2014
|
1.19
|
|
59
|
Health care expenditures associated with skeletal fractures among Medicare beneficiaries, 1999-2005.
|
J Bone Miner Res
|
2009
|
1.18
|
|
60
|
Racial disparities in the receipt of osteoporosis related healthcare among community-dwelling older women with arthritis and previous fracture.
|
J Rheumatol
|
2005
|
1.12
|
|
61
|
Quality indicators for the care of osteoarthritis in vulnerable elders.
|
J Am Geriatr Soc
|
2007
|
1.12
|
|
62
|
Gout-related health care utilization in US emergency departments, 2006 through 2008.
|
Arthritis Care Res (Hoboken)
|
2013
|
1.10
|
|
63
|
Developing a provisional definition of flare in patients with established gout.
|
Arthritis Rheum
|
2012
|
1.10
|
|
64
|
Racial disparities in osteoporosis prevention in a managed care population.
|
South Med J
|
2003
|
1.10
|
|
65
|
Using a modified nominal group technique to elicit director of nursing input for an osteoporosis intervention.
|
J Am Med Dir Assoc
|
2006
|
1.10
|
|
66
|
Potential and pitfalls of using large administrative claims data to study the safety of osteoporosis therapies.
|
Curr Rheumatol Rep
|
2011
|
1.10
|
|
67
|
Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population.
|
Arthritis Care Res (Hoboken)
|
2012
|
1.09
|
|
68
|
The PAADRN study: a design for a randomized controlled practical clinical trial to improve bone health.
|
Contemp Clin Trials
|
2012
|
1.09
|
|
69
|
Estrogen and other female reproductive risk factors are not strongly associated with the development of rheumatoid arthritis in elderly women.
|
Semin Arthritis Rheum
|
2003
|
1.07
|
|
70
|
Pathophysiology, clinical presentation and treatment of gout.
|
Drugs
|
2006
|
1.06
|
|
71
|
Is withholding osteoporosis medication after fracture sometimes rational? A comparison of the risk for second fracture versus death.
|
J Am Med Dir Assoc
|
2010
|
1.06
|
|
72
|
Death, debility, and destitution following hip fracture.
|
J Gerontol A Biol Sci Med Sci
|
2013
|
1.03
|
|
73
|
Bridging the osteoporosis quality chasm.
|
J Bone Miner Res
|
2009
|
1.03
|
|
74
|
Medication errors with the use of allopurinol and colchicine: a retrospective study of a national, anonymous Internet-accessible error reporting system.
|
J Rheumatol
|
2006
|
1.03
|
|
75
|
From bone biology to clinical outcome: state of the art and future perspectives.
|
Ann Rheum Dis
|
2010
|
1.02
|
|
76
|
Prevalence of osteoporosis and osteopenia among African Americans with early rheumatoid arthritis: the impact of ethnic-specific normative data.
|
J Natl Med Assoc
|
2005
|
1.02
|
|
77
|
The delivery of evidence-based preventive care for older Americans with arthritis.
|
Arthritis Res Ther
|
2010
|
1.02
|
|
78
|
Communicating non-steroidal anti-inflammatory drug risks: verbal counseling, written medicine information, and patients' risk awareness.
|
Patient Educ Couns
|
2010
|
1.02
|
|
79
|
The effect of thiazolidinediones on BMD and osteoporosis.
|
Nat Clin Pract Endocrinol Metab
|
2008
|
1.02
|
|
80
|
Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs.
|
Am J Med
|
2013
|
1.01
|
|
81
|
The association of race/ethnicity with the receipt of traditional and alternative arthritis-specific health care.
|
Med Care
|
2003
|
1.01
|
|
82
|
Racial/ethnic disparities in patient-reported nonsteroidal antiinflammatory drug (NSAID) risk awareness, patient-doctor NSAID risk communication, and NSAID risk behavior.
|
Arthritis Rheum
|
2007
|
1.00
|
|
83
|
Osteoporosis in the home health care setting: A window of opportunity?
|
Arthritis Rheum
|
2006
|
0.98
|
|
84
|
Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link?
|
Arthritis Res Ther
|
2009
|
0.98
|
|
85
|
Drug Insight: choosing a drug treatment strategy for women with osteoporosis-an evidence--based clinical perspective.
|
Nat Clin Pract Rheumatol
|
2008
|
0.97
|
|
86
|
Brief report: incidence of selected opportunistic infections among children with juvenile idiopathic arthritis.
|
Arthritis Rheum
|
2013
|
0.96
|
|
87
|
Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study.
|
Ann Rheum Dis
|
2011
|
0.96
|
|
88
|
Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW).
|
Bone
|
2011
|
0.96
|
|
89
|
Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients.
|
Arthritis Care Res (Hoboken)
|
2012
|
0.96
|
|
90
|
Developments in glucocorticoid therapy.
|
Rheum Dis Clin North Am
|
2005
|
0.96
|
|
91
|
Osteoporotic fractures in older adults.
|
Best Pract Res Clin Rheumatol
|
2006
|
0.95
|
|
92
|
Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis?
|
Arthritis Rheum
|
2011
|
0.95
|
|
93
|
The role of health literacy and written medicine information in nonsteroidal antiinflammatory drug risk awareness.
|
Ann Pharmacother
|
2010
|
0.95
|
|
94
|
Association of infections and tuberculosis with antitumor necrosis factor alpha therapy.
|
Curr Opin Rheumatol
|
2008
|
0.93
|
|
95
|
Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases.
|
Arthritis Rheum
|
2013
|
0.92
|
|
96
|
Patient-reported communications with pharmacy staff at community pharmacies: the Alabama NSAID Patient Safety Study, 2005-2007.
|
J Am Pharm Assoc (2003)
|
2010
|
0.92
|
|
97
|
Bone mineral density changes within six months of renal transplantation.
|
Transplantation
|
2003
|
0.91
|
|
98
|
Health-related quality of life among self-reported arthritis sufferers: effects of race/ethnicity and residence.
|
Qual Life Res
|
2006
|
0.91
|
|
99
|
Validation of diagnostic codes for subtrochanteric, diaphyseal, and atypical femoral fractures using administrative claims data.
|
J Clin Densitom
|
2011
|
0.91
|
|
100
|
Health-related quality of life in Gulf War era military personnel.
|
Am J Epidemiol
|
2002
|
0.91
|
|
101
|
Patterns of osteoporosis treatment change and treatment discontinuation among commercial and Medicare Advantage Prescription Drug members in a national health plan.
|
J Eval Clin Pract
|
2011
|
0.91
|
|
102
|
New insights into gout epidemiology.
|
Curr Opin Rheumatol
|
2006
|
0.90
|
|
103
|
Serum urate association with hypertension in young adults: analysis from the Coronary Artery Risk Development in Young Adults cohort.
|
Ann Rheum Dis
|
2012
|
0.90
|
|
104
|
Quality health care gaps in osteoporosis: how can patients, providers, and the health system do a better job?
|
Curr Osteoporos Rep
|
2009
|
0.90
|
|
105
|
Serum urate and its relationship with alcoholic beverage intake in men and women: findings from the Coronary Artery Risk Development in Young Adults (CARDIA) cohort.
|
Ann Rheum Dis
|
2010
|
0.89
|
|
106
|
Management of osteoporosis among home health and long-term care patients with a prior fracture.
|
South Med J
|
2009
|
0.89
|
|
107
|
Nonsteroidal antiinflammatory drug toxicity monitoring and safety practices.
|
J Rheumatol
|
2003
|
0.89
|
|
108
|
Osteoporosis diagnosis and medical treatment.
|
Orthop Clin North Am
|
2013
|
0.89
|
|
109
|
Physicians' explanations for apparent gaps in the quality of rheumatology care: results from the US Medicare Physician Quality Reporting System.
|
Arthritis Care Res (Hoboken)
|
2013
|
0.88
|
|
110
|
Bringing it all together: a novel approach to the development of response criteria for chronic gout clinical trials.
|
J Rheumatol
|
2011
|
0.88
|
|
111
|
Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
|
J Rheumatol
|
2009
|
0.88
|
|
112
|
Regional variation in the denial of reimbursement for bone mineral density testing among US Medicare beneficiaries.
|
J Clin Densitom
|
2008
|
0.87
|
|
113
|
Health and happiness among older adults: a community-based study.
|
J Health Psychol
|
2009
|
0.86
|
|
114
|
The effects of physician specialty and patient comorbidities on the use and discontinuation of coxibs.
|
Arthritis Rheum
|
2003
|
0.85
|
|
115
|
Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients.
|
Arthritis Care Res (Hoboken)
|
2015
|
0.85
|
|
116
|
Bisphosphonates for osteoarthritis prevention: "Holy Grail" or not?
|
Ann Rheum Dis
|
2008
|
0.85
|
|
117
|
A close examination of healthcare expenditures related to fractures.
|
J Bone Miner Res
|
2013
|
0.84
|
|
118
|
Use of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United States.
|
Arthritis Care Res (Hoboken)
|
2014
|
0.84
|
|
119
|
Association between being African-American, serum urate levels and the risk of developing hyperuricemia: findings from the Coronary Artery Risk Development in Young Adults cohort.
|
Arthritis Res Ther
|
2012
|
0.83
|
|
120
|
Improving osteoporosis care in high-risk home health patients through a high-intensity intervention.
|
Contemp Clin Trials
|
2011
|
0.83
|
|
121
|
Obesity, health-care utilization, and health-related quality of life after fracture in postmenopausal women: Global Longitudinal Study of Osteoporosis in Women (GLOW).
|
Calcif Tissue Int
|
2014
|
0.83
|
|
122
|
Glucocorticoids and the risk of osteoporosis.
|
Expert Opin Drug Saf
|
2009
|
0.83
|
|
123
|
Drug treatment of hyperuricemia to prevent cardiovascular outcomes: are we there yet?
|
Am J Cardiovasc Drugs
|
2012
|
0.83
|
|
124
|
Management of hyperuricemia and gout in CKD.
|
Am J Kidney Dis
|
2008
|
0.82
|
|
125
|
Association of health-related quality of life with dual use of prescription and over-the-counter nonsteroidal antiinflammatory drugs.
|
Arthritis Rheum
|
2008
|
0.82
|
|
126
|
Glucocorticoid-related bone changes from endogenous or exogenous glucocorticoids.
|
Curr Opin Endocrinol Diabetes Obes
|
2013
|
0.82
|
|
127
|
Osteopenia: debates and dilemmas.
|
Curr Rheumatol Rep
|
2013
|
0.81
|
|
128
|
Prevention and treatment of glucocorticoid-induced osteoporosis.
|
Curr Osteoporos Rep
|
2007
|
0.81
|
|
129
|
Association between anti-TNF-α therapy and interstitial lung disease.
|
Pharmacoepidemiol Drug Saf
|
2013
|
0.81
|
|
130
|
Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
|
Bone
|
2010
|
0.81
|
|
131
|
Long-term safety concerns of antiresorptive therapy.
|
Rheum Dis Clin North Am
|
2011
|
0.81
|
|
132
|
Preliminary competencies for comparative effectiveness research.
|
Clin Transl Sci
|
2012
|
0.81
|
|
133
|
Association between anti-TNF-α therapy and all-cause mortality.
|
Pharmacoepidemiol Drug Saf
|
2012
|
0.80
|
|
134
|
Ethnic variations in the prevalence of metabolic bone disease among HIV-positive patients with lipodystrophy.
|
AIDS Res Hum Retroviruses
|
2006
|
0.80
|
|
135
|
Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout.
|
Core Evid
|
2010
|
0.79
|
|
136
|
Using single-item health literacy screening questions to identify patients who read written nonsteroidal anti-inflammatory medicine information provided at pharmacies.
|
J Health Commun
|
2010
|
0.79
|
|
137
|
Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates?
|
Rev Endocr Metab Disord
|
2006
|
0.79
|
|
138
|
Official Positions for FRAX(®) clinical regarding glucocorticoids: the impact of the use of glucocorticoids on the estimate by FRAX(®) of the 10 year risk of fracture from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®).
|
J Clin Densitom
|
2011
|
0.79
|
|
139
|
Serum urate levels and consumption of common beverages and alcohol among Chinese in Singapore.
|
Arthritis Care Res (Hoboken)
|
2013
|
0.79
|
|
140
|
Use of health plan combined with registry data to predict clinical trial recruitment.
|
Clin Trials
|
2013
|
0.78
|
|
141
|
Trends in the utilization and outcomes of Medicare patients hospitalized for hip fracture, 2000-2008.
|
J Aging Health
|
2014
|
0.78
|
|
142
|
A group randomized trial to improve safe use of nonsteroidal anti-inflammatory drugs.
|
Am J Manag Care
|
2005
|
0.78
|
|
143
|
Gout treatment: what is evidence-based and how do we determine and promote optimized clinical care?
|
Curr Rheumatol Rep
|
2005
|
0.78
|
|
144
|
A randomized trial of a mailed intervention and self-scheduling to improve osteoporosis screening in postmenopausal women.
|
J Bone Miner Res
|
2012
|
0.78
|
|
145
|
Does medication adherence itself confer fracture protection? An investigation of the healthy adherer effect in observational data.
|
Arthritis Care Res (Hoboken)
|
2012
|
0.77
|
|
146
|
Osteoporosis: evaluation and treatment.
|
Curr Womens Health Rep
|
2003
|
0.77
|
|
147
|
From fracture risk prediction to evaluating fracture patterns: recent advances in the epidemiology of osteoporosis.
|
Curr Rheumatol Rep
|
2012
|
0.77
|
|
148
|
Improving quality of care in osteoporosis: opportunities and challenges.
|
Curr Rheumatol Rep
|
2008
|
0.77
|
|
149
|
Effect of self-referral on bone mineral density testing and osteoporosis treatment.
|
Med Care
|
2014
|
0.77
|
|
150
|
Is febuxostat a more effective treatment for hyperuricemia and gout than allopurinol?
|
Nat Clin Pract Rheumatol
|
2006
|
0.77
|
|
151
|
OMERACT endorsement of measures of outcome for studies of acute gout.
|
J Rheumatol
|
2013
|
0.76
|
|
152
|
Prevention of osteoporosis associated with chronic glucocorticoid therapy.
|
JAMA
|
2006
|
0.76
|
|
153
|
Reply: To PMID 22473917.
|
Arthritis Care Res (Hoboken)
|
2013
|
0.76
|
|
154
|
Using tablet computers compared to interactive voice response to improve subject recruitment in osteoporosis pragmatic clinical trials: feasibility, satisfaction, and sample size.
|
Patient Prefer Adherence
|
2013
|
0.76
|
|
155
|
Effect of racial differences on ability to afford prescription medications.
|
Am J Health Syst Pharm
|
2008
|
0.76
|
|
156
|
Prevention and treatment of bone changes associated with exposure to glucocorticoids.
|
Curr Osteoporos Rep
|
2013
|
0.76
|
|
157
|
Ibandronate injections in postmenopausal women with osteoporosis.
|
Curr Rheumatol Rep
|
2007
|
0.75
|
|
158
|
Is two better than one? Combining antiresorptive and anabolic osteoporosis medications.
|
Curr Osteoporos Rep
|
2011
|
0.75
|
|
159
|
Unbalanced regulation of over-the-counter analgesics: the lesser of two evils?
|
Pharmacoepidemiol Drug Saf
|
2006
|
0.75
|
|
160
|
Serum urate, menopause, and postmenopausal hormone use: from eminence to evidence-based medicine.
|
Arthritis Res Ther
|
2008
|
0.75
|
|
161
|
RE: Drug risk assessment and data reuse.
|
Pharmacoepidemiol Drug Saf
|
2014
|
0.75
|
|
162
|
Balancing bones and bucks among new glucocorticoid users.
|
J Rheumatol
|
2003
|
0.75
|
|
163
|
The use of zoledronic acid for osteoporosis.
|
Curr Rheumatol Rep
|
2008
|
0.75
|
|
164
|
Racial Differences and Disparities in Osteoporosis-related Bone Health: Results From the PAADRN Randomized Controlled Trial.
|
Med Care
|
2017
|
0.75
|
|
165
|
Therapeutic advances in calcium and vitamin D for osteoporosis.
|
Curr Rheumatol Rep
|
2008
|
0.75
|
|
166
|
Biologics and heart failure in rheumatoid arthritis: are we any wiser?
|
Curr Opin Rheumatol
|
2008
|
0.75
|
|
167
|
Denosumab in postmenopausal women with low bone mineral density.
|
Curr Rheumatol Rep
|
2007
|
0.75
|
|
168
|
Study design considerations for a large simple trial of bisphosphonates.
|
Curr Opin Rheumatol
|
2013
|
0.75
|
|
169
|
Treatment of acute gout-like arthritis in an emergency setting: prednisolone versus indomethacin.
|
Nat Clin Pract Rheumatol
|
2007
|
0.75
|
|
170
|
Are glucocorticoids equivalent to NSAIDs for the treatment of gout flares?
|
Nat Clin Pract Rheumatol
|
2008
|
0.75
|
|
171
|
Screening Questions for Nonsteroidal Anti-inflammatory Drug Risk Knowledge.
|
J Patient Saf
|
2014
|
0.75
|
|
172
|
Documented tuberculin skin testing among infliximab users following a multi-modal risk communication interventions.
|
Pharmacoepidemiol Drug Saf
|
2006
|
0.75
|
|
173
|
Tumor necrosis factor, tuberculosis, testing, and treatment: teeing up the questions.
|
Arthritis Care Res (Hoboken)
|
2013
|
0.75
|
|
174
|
Patient-reported reasons for nonadherence to recommended osteoporosis pharmacotherapy.
|
J Am Pharm Assoc (2003)
|
2017
|
0.75
|
|
175
|
How to ascertain drug safety in the context of benefit. Controversies and concerns.
|
J Rheumatol
|
2009
|
0.75
|
|
176
|
Improving the quality of clinical care for patients with osteoporosis.
|
Expert Rev Pharmacoecon Outcomes Res
|
2006
|
0.75
|
|
177
|
Preface.
|
Best Pract Res Clin Rheumatol
|
2009
|
0.75
|
|
178
|
A group-randomized trial of shared decision making for non-steroidal anti-inflammatory drug risk awareness: primary results and lessons learned.
|
J Eval Clin Pract
|
2014
|
0.75
|
|
179
|
Evaluating and improving the quality of care in rheumatic disease.
|
Expert Rev Pharmacoecon Outcomes Res
|
2004
|
0.75
|